Cutaneous Lymphomas: Molecular Pathways Leading to New Drugs  by Dummer, Reinhard et al.
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Currently, cutaneous lymphomas represent a paradigm for the heterogeneity and the dynamic variability
of neoplastic disorders resulting in the accumulation of clonal lymphocytes in the skin, and thus mirror
the complexity of lymphocytic populations. Increasing knowledge and insight in pathobiology offer new
opportunities for targeted interventions to selectively hit the tumor populations. mAbs, rexinoids, small kinase
inhibitors, or molecules interfering with methylation or histone acetylation contribute to disease control. The
rational and well-coordinated application of these tools, together with improved chemotherapeutic options,
will hopefully further improve treatment success in the near future.
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INTRODUCTION
Primary cutaneous lymphomas (PCLs)
represent a spectrum of primary skin
lymphoproliferative neoplasms and are
the second most common manifesta-
tion of extranodal non-Hodgkin lym-
phomas. The group includes primary
cutaneous T-cell lymphomas (CTCLs),
primary cutaneous B-cell lymphomas
(CBCLs), and a separate entity of
cutaneous blastic plasmacytoid dendri-
tic cell neoplasms (Willemze et al.,
2005; Kempf and Sander, 2010). The
name ‘‘primary’’ emphasizes the initial
disease presentation in the skin, with
no indication of extracutaneous mani-
festations detectable by imaging proce-
dures at the time of diagnosis (Burg
et al., 2005; Willemze et al., 2005).
However, PCLs are neoplasms of the
lymphoreticular system and, by defini-
tion, systemic diseases with circulating
tumor cells. This is obvious in Se´zary
syndrome (SS) (Vonderheid et al., 2002;
Olsen et al., 2007a). CTCLs represent
the most common subgroup of PCLs
and include three major entities: myco-
sis fungoides (MF), SS, and primary
cutaneous CD30þ lymphoproliferative
diseases, which together account for
more than 90% of all CTCLs. In the
group of CBCLs there are following
entities: primary cutaneous follicular
centre lymphoma (PCFCL), primary
cutaneous marginal zone lymphoma
(PCMZL), intravascular CBCL, primary
cutaneous diffuse large B cell (PCLBCL)
leg type, and PCBCL, other. PCFCL and
PCMZL represent the most common
disease entities in CBCLs (11% and 7%,
respectively), whereas PCLBCL leg type
are quite rare (o1% of all CLs). Most of
the CBCL, except for the diffuse large
CBCL leg type and intravascular CBCLs,
are considered as low-grade neoplasms
(Willemze et al., 2005; Kempf and
Sander, 2010).
Immunopathogenesis of MF and SS
is characterized by the accumulation
of skin-homing clonal T cells with a
memory phenotype that displays a Th2
cytokine profile in most cases (Dummer
et al., 1993, 1996; Hahtola et al., 2006).
The tumor cell population in most CBCLs
is derived from the germinal center or
marginal zone B lymphocytes (Kuppers,
2005). Clinical manifestations differ
between the PCL entities, which are also
characterized by a variety of histologi-
cal, immunophenotypical, cytogenetic,
and molecular features (Supplementary
Table 1, Supplementary Figure 1 online).
Recent progress in our understand-
ing of the clinical and molecular
features of PCL can be illustrated by
the advances in detailed classification
of these entities incorporated in the new
World Health Organization/International
Society for Cutaneous Lymphomas/Euro-
pean Organization of Research and
Treatment of Cancer system as compared
with earlier versions (Olsen et al.,
2007a). Taken together, the new classifi-
cation serves nowadays as an invaluable
connection between the dermatologists,
hematologists, and oncologists involved
in the treatment of PCLs, which contri-
butes to the design of therapeutic trials in
uniform patient populations with repro-
ducible diagnosis and stage.
Existing therapies have been sum-
marized in several comprehensive
review articles (Kerl and Cerroni,
2006; Prince et al., 2009c; Akilov and
Geskin, 2011; Foss et al., 2011; Martin
and Duvic, 2011; Olsen et al., 2011;
Wong et al., 2011). The purpose of
current review is to discuss emerging
therapeutic options for PCLs. Here we
will focus on several types of molecules
& 2012 The Society for Investigative Dermatology www.jidonline.org 517
PERSPECTIVE
Received 25 October 2010; revised 27 September 2011; accepted 30 September 2011; published online 8 December 2011
1Department of Dermatology, University Hospital Zu¨rich, Zu¨rich, Switzerland
Correspondence: Reinhard Dummer, Department of Dermatology, University Hospital Zu¨rich, Gloriastrasse 31, Zu¨rich 8091, Switzerland.
E-mail: reinhard.dummer@usz.ch
Abbreviations: CBCL, cutaneous B-cell lymphomas; CTCL, cutaneous T-cell lymphomas; MAPK, mitogen-activated protein kinase; PCL, primary cutaneous
lymphomas; SS, Se´zary syndrome
that are opening new promising per-
spectives for implementation in clinical
practice.
TARGETS FOR CLINICAL
INTERVENTIONS
The concept of targeted typically per-
sonalized therapy is a key element of
current cancer development. Some attrac-
tive targets are based on the phenom-
enon of ‘‘oncogene addiction’’, which
makes cancer cells dependent on the
specific oncogenic signaling pathways
that have been activated in order to
give tumor cells a survival advantage.
Therapeutic strategies for PCL treat-
ment, which we will discuss further,
are presented in Figure 1.
Surface targets
Molecules that are on the cell surface
represent excellent targets for therapeu-
tic interventions if their expression is
restricted to the tumor cell population.
The search for specific markers of tumor
cells in PCL is still open (see Supple-
mentary Table 1 online). Very recent
reports further detailed the phenotype
of the clonal T-cell memory cells in SS
and MF patients, demonstrating that
circulating tumor cells in patients
with SS are central memory T cells
co-expressing CCR7, L-selectin, CCR4,
and CD27, whereas in MF patients
lesional tumor cells are effector T cells
that lack CCR7/L-selectin but express
CCR4 and CLA. Interestingly, the malig-
nant populations in both entities have a
distinct high-scatter profile that differ-
entiates them from benign clonal T cells
(Campbell et al., 2010; Clark et al.,
2011). Other promising markers that are
actively studied in PCLs include IL-17,
PD-1, and NKp46 (Samimi et al., 2010;
Wu et al., 2010; Bensussan et al., 2011;
Krejsgaard et al., 2011). Such distinctive
observations may provide the rationale
for the development of blocking anti-
bodies (Abs) or chemical agonists.
After years of frustration, recombi-
nant biotechnologies have successfully
produced powerful mAb and fusion
molecules. The best example certainly
is the anti-CD20 Ab Rituximab, which
is widely used in B-cell malignancies
including CBCLs and more recently
in autoimmune disorders. Cellular
and molecular responses during the
Rituximab treatment have been sum-
marized (Jazirehi and Bonavida, 2005).
In addition to the Ab-dependent cellu-
lar cytotoxicity and complement acti-
vation, Rituximab is able to impact
several major survival pathways. It
can downregulate the mitogen-acti-
vated protein kinase (MAPK) pathway,
which results in the inhibition of
the IL-10/IL-10R autocrine/paracrine
cytokine autoregulatory loop. As a con-
sequence, a cascade of downregula-
tions follows, including STAT3 activity,
BCL2 expression, and the ERK1/2 and
NF-kB pathways, leading to the inhibi-
tion of BCL-xL. Notably, the chemo-
sensitization phenomenon observed
during the combined use of Rituximab
with chemotherapy is attributed to the
downregulation of BCL2 and negative
regulation of major survival pathways
(Jazirehi and Bonavida, 2005; Amoroso
et al., 2011). The Abs used in CTCLs so
far target a wide spectrum of lympho-
cytic population.
The anti-CD52 Ab, Alemtuzumab,
depletes B and T cells. High-dose ther-
apy, as initially suggested for CLL, results
in significant immunosuppression. Low-
dose therapy, however, appears more
attractive as it is well tolerated and
is efficient in erythrodermic/leukemic
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Figure 1. Targeted therapy strategies in primary cutaneous lymphomas. Left panel (Target) summarizes known molecular pathogenic events described
for PCLs. Right panel (Tool) summarizes emerging targeted interventions. Vertically, the figure is divided according to cellular compartments where targets
are localized: membrane, cytoplasm, and nucleus. All abbreviations present common gene names. The P symbol corresponds to phosphorylation process.
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Se´zary patients. Reported overall res-
ponse rate was as high as 84%; however,
median progression-free survival was 6
months (Bernengo et al., 2007; Querfeld
et al., 2009).
The anti-CD4 Ab, Zanolimumab,
affects all T-helper populations including
‘‘normal’’ T-helper cells that are essen-
tial for maintaining an adequate control
of viral and opportunistic infections.
Therefore, infectious complications are
frequent, including Epstein–Barr virus
reactivation, even if Zanolimumab is
used in low dosage. Results of two
recent Phase II studies in CTCL patients
showed Zanolimumab efficacy mostly in
refractory MF patients, with an overall
response rate of 58% and median
response duration of 81 weeks. Never-
theless, the development of this Ab was
discontinued (Kim et al., 2007).
Consequently, there is still an urgent
need for the identification of tumor
cell–specific surface targets in CTCLs.
Recently developed Abs may help over-
come this limitation by targeting che-
mokine receptors, CCR4 (Yamamoto
et al., 2010), the killer cell immunoglob-
ulin–like receptor CD158K (KIR3DL2),
or CD30 (Ansell et al., 2007; Oflazoglu
et al., 2008; Younes et al., 2010).
Topical immunotherapy
Cutaneous lymphomas depend on the
fragile network of interactions between
the dominant tumor cell populations
and the cutaneous microenvironment.
This network is orchestrated by tissue
molecules, growth factors, cytokines,
and chemokines. Aspects of PCL im-
munopathogenesis, including the role
of IL-2, IL-12, IL-15, and other cyto-
kines, are discussed in detail elsewhere
(Foss et al., 2011; Olsen et al., 2011).
The PCL lesions are well accessible
to direct injections. Therefore, intrale-
sional approaches appear promising,
especially if they result in systemic
immune responses.
A third-generation adenoviral vector
encoding the IFN-g (TG1042) was
successfully tested in clinical trials. It
was shown that the vector-encoded
transgene is expressed locally indepen-
dent of the presence of neutralizing
anti-adenovirus Abs (Dummer et al.,
2004). Subsequent gene expression
analysis revealed that intralesional
IFN-g expression, together with the
induction of a type I IFN response,
facilitates the clinical response (Urose-
vic et al., 2007). The injection of
TG1042 results in local secretion of
IFN-g and induces 15% of complete
and 31% of partial local response rates
in CTCL patients. Global response to
TG1042 injections is also seen in a
substantial 23% of treated patients,
marked by the disappearance of distant
lesions. We are convinced that sys-
temic immune activation is involved in
the clearance or reduction in tumor
size of non-injected lymphoma lesions
observed in some of the patients
studied (Dummer et al., 2010).
Toll-like receptors (TLRs) recognize
conserved pathogen-associated mole-
cular patterns of microbes and viruses
(Medzhitov and Janeway, 2000).
Manipulation of the innate immune
response through TLR activation func-
tions as a bridge toward enhancement
of tumor-specific acquired immunity
(Hoebe et al., 2004). The small-mole-
cule TLR7 agonist, Imiquimod, induces
IFN-a production from plasmacytoid
dendritic cells, as well as pro-inflam-
matory cytokines from other cells
(Urosevic et al., 2005). Imiquimod has
induced regression in PCL lesions after
topical administration (Suchin et al.,
2002; Dummer et al., 2003). Other TLR
agonists, such as Resimiquimod, which
targets TLR7 and 8, might be very
useful for inducing efficient immune
responses to PCL, especially when
applied in combination with other
therapies. Safety and tolerability of a
TLR9 agonist, PF-3512676, was recently
assessed in a Phase I trial. Although this
trial was not designed to evaluate the
efficacy of the compound, reported
response rate was 32%, and effects were
ongoing by the end of the study (Kim
et al., 2010). Another currently investi-
gated approach uses treatment with low-
dose irradiation to induce tumor damage
and antigen release in combination
with the TLR9 agonist GCP. Similar to
the adeno–IFN-g approach, regressions
of distant lesions have been documented
(Brody et al., 2010).
Small-molecule tyrosine kinase inhibitors
One of the first classes of targeted small
molecule therapeutics introduced in
the clinical practice were small-mole-
cule tyrosine kinase inhibitors (TKIs). A
large number of protein types involved
in signaling can possess a kinase
activity. Targeting such pathways with
TKI can be used in different cancer
types based on the molecular charac-
teristics of the signaling pathways in
each cancer type. Major signaling
pathways that are affected by malig-
nant transformation in PCL include
activation of JAK-STAT and PI3/AKT/
mTOR signaling cascades. Research
efforts are also directed toward the
NOTCH, RAS/RAF/MEK/ERK, and
Polo-like kinase pathways, which can
all be connected to the cell cycle
control by P15/P16 oncogenic network
(Kamstrup et al., 2010; Nihal et al.,
2011; Stutz et al., 2011).
Small-molecule compounds inhibit-
ing members of these pathways are
being actively developed. Dynamic
interconnection of signaling networks
within a cancer cell serves as a
rationale to discuss different kinase
inhibitors in the context of therapy for
PCL.
Several in vitro studies reported that
downregulation of NF-kB signaling
pathway induces cell death in CTCL
tumor cells, which makes it a promis-
ing candidate for future drug develop-
ment (Sors et al., 2006, 2008; Kiessling
et al., 2009; Zhang et al., 2010). Recent
data show that members of Src kinase
family are expressed on CTCL malig-
nant cells (Kennah et al., 2009; Krejs-
gaard et al., 2009). Human SRC family
of kinases, SFKs, consist of several non-
receptor protein tyrosine kinases in-
cluding SRC, LCK, BLK, and HCK,
which are involved in transcriptional
regulation of a variety of cellular
processes relevant to tumorigenesis
(Thomas and Brugge, 1997). One of
the available and registered SFK inhi-
bitors is Dasatinib (BMS-354825, Spry-
cel), which is an oral dual inhibitor of
BCR/ABL and SRC family tyrosine
kinases. Interestingly, Dasatinib is re-
ported to be active in malignant CTCL
by blocking BLK activity, whose ex-
pression can be mediated by constant
activation of NF-kB signaling (Krejs-
gaard et al., 2009). These data suggest
that Src family kinase inhibitors may
also have a potential in the treatment of
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PCL, as well as provide the link for use
of RAS inhibitors in PCL patients.
The MAPK signal transduction net-
work is one of the largest signaling
knots and is used by a number of
signaling pathways. One signaling axis
stems from the RAS family of oncopro-
teins, leading to the activation of RAF,
MEK (MAP2K), and ERK 1/2 protein
kinases in order to regulate (commu-
nicate) cell proliferative and survival
signals. The pathway is sometimes
referred to as the RAS/RAF/MEK/ERK
pathway and is considered to have a
major role in the transmission of pro-
liferative signals from receptors loca-
lized in the cell membrane. Being such
a vast and important network, it is not
surprising that roughly one-third of all
cancers harbor aberrations leading
to its constitutive activation (Martin,
2003; Dhillon et al., 2007). A recent
report showed that a few CTCL biopsies
(B10%) harbor mutations in RAS
family oncogenes, namely NRAS
(NRASQ61K) and KRAS (KRASG13D). All
patients with mutations observed in this
study were stage IV and showed
significantly decreased overall survival
compared with stage IV patients with-
out mutations (Kiessling et al., 2011). It
is interesting to note that during this
high-throughput mutation screening of
CTCL patients, other mutations were
not registered. This observation opens a
possibility for using RAS, RAF, or MEK
inhibitors as a second-line therapeutic
option for advanced and relapsing
patients who present mutations in
RAS family. Notably, multikinase inhi-
bitors such as Sorafenib and MEK
kinase inhibitors appear promising.
Current ongoing attempts to evaluate
the efficacy of these drugs in skin
cancer are focused mostly on advanced
melanoma.
The PI3/AKT/mTOR pathway is a
distinct axis within the MAPK network,
which provides a promising opportu-
nity for tumor growth inhibition. Initial
data were obtained by Kremer et al
(2010), where authors investigated the
mTOR pathway activation in primary
cells from several SS patients and
established CTCL cell lines. Further-
more, tumor growth reduction upon
rapamycin treatment was assessed
using CTCL cell line xenograft animal
model (Kremer et al., 2010). These
results suggest that PI3/AKT/mTOR
signaling is important in CTCL tumor
growth, and one can anticipate that
broadening the spectrum of inhibitors
targeting other kinases of this pathway
shall also be investigated.
Another possible target of TKIs is the
JAK-STAT pathway, as its activation is
one of the frequent events in CTCL
tumor cells. Although gain of STAT3
and STAT5A/STAT5B genes was report-
ed to be a highly reoccurring aberration
in Se´zary cells (Vermeer et al., 2008),
the signaling balance between these
transcription factors is more complex.
STAT3 activation through the protein
phosphorylation is constitutive in
CTCL tumor cells and appears to be
dependent on factors present in the
tumor microenvironment, such as IL-2
(Zhang et al., 1996; Eriksen et al., 2001;
Kasprzycka et al., 2008; van Kester
et al., 2008). STAT5 is reported to be
overexpressed or solely present as a
proteolytically processed form with
truncated C terminus (Mitchell et al.,
2003). Very recent studies indicate that
constitutive activation of STAT3 can
be driven by autocrine production of
IL-21, whereas STAT5 phosphorylation
is induced by to IL-2, IL-7, and IL-15
(Krejsgaard et al., 2008; van der Fits
et al., 2011a). JAK3/STAT3 axis of the
pathway in turn promotes IL-17 produc-
tion by malignant CTCL cells, giving the
link to inflammatory component of the
disease (Krejsgaard et al., 2011). Phos-
phorylation of JAK1 and JAK2, but
not activating mutations in these two
enzymes, also contributes to the con-
stitutive STAT3 activation, which is
independent of downregulation or loss
of SHP-1 tyrosine phosphatase. In this
respect, the use of JAK inhibitors
represents a promising therapeutic op-
tion already confirmed by in vitro data
(McKenzie et al., 2011).
Clinical use of TKI in CLs is
so far limited. Results of a recently
completed Phase II trial of enzastaurin
(LY317615), a selective protein kinase
C-b inhibitor, are awaiting publication
(Querfeld et al., 2011). This study was
initiated based on the promising pre-
clinical data showing that enzastaurin
can induce apoptosis in CTCL cells
(Querfeld et al., 2006). The compound
is stated to be well tolerated, but with
moderate biological activity. This ob-
servation led to the thorough molecular
investigation of complementary signal-
ing pathways, which identified glyco-
gen synthase kinase 3 inhibition as
a possible combination strategy to
increase the efficacy of enzastaurin
(Rovedo et al., 2011).
Anti-angiogenic therapy. Although the
exact mechanism of the angiogenesis
in PCL remains incompletely under-
stood, the role of angiogenesis, as well
as lymphangiogenesis, is well accepted
(Mandriota et al., 2001; Skobe et al.,
2001; Cao, 2005). Angiogenesis is
controlled by a signaling network
originating from several receptor tyro-
sine kinases named vascular endothe-
lial growth factor (VEGF) receptors:
VEGFR-1, VEGFR-2, and VEGFR-3
(Lohela et al., 2009; Mumprecht and
Detmar, 2009). Blocking of these re-
ceptors is thought to have an impact on
vascularization, and therefore several
TKIs were developed to control and
inhibit this tumor property. We and
others showed that both vasculariza-
tion processes—angiogenesis and lym-
phangiogenesis—are enhanced in PCL
(Vacca et al., 1997; Schaerer et al.,
2000; Mazur et al., 2004; Karpova
et al., 2010). It has been demonstrated
that expression of one of the angio-
genic factors, VEGF, in skin lesions of
CTCL patients is JAK3 and JNK depen-
dent and can be blocked by the JAK3
and JNK inhibitor, curcumin (Krejs-
gaard et al., 2006). However, the
increased number of blood and lym-
phatic vessels in CLs provides the basis
for developing a rationale to assess
therapeutic strategies that counteract
active vascularization. For example,
Pazopanib (GW786034) is a potent
oral multi-targeted angiogenesis inhibi-
tor that targets VEGFR-1, VEGFR-2,
VEGFR-3, PDGFR-a/b, and c-KIT. It
seems to be well tolerated and has
been approved for use in renal cell
carcinoma, and is actively investigated
in a variety of malignancies including
ovarian cancer, nonsmall cell lung
cancer, and soft tissue sarcoma (Sleijfer
et al., 2009). Another exciting possi-
bility to influence vascularization is
through the treatment with rapamycin
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or rapalogs, as the PI3K/AKT/mTOR
pathway is known to regulate VEGF
expression through regulation of hy-
poxia inducible factor-1a transcription
factor (Kremer et al., 2010).
Cell cycle control P15/P16 in CLs. The
loss of P16 activity allows the activa-
tion of the cyclin-dependent kinases
(CDKs) 4 and 6 by the RAS proto-
oncogene. Inactivation of P15 and P16
is quite often observed in advanced
CTCLs and CBCLs, making CDK4 and
6 activation putative causes of the
increased cell proliferation. In this
respect, targeting of cyclin-dependent
kinases might represent a promising
therapeutic intervention. An example
could be Seliciclib (CYC202, R-roscov-
itine), a selective CDK inhibitor that has
been reported to be active in mantle
cell lymphoma (Lacrima et al., 2005).
Presently, there are more than 10 CDK
inhibitor compounds being tested in
clinical trials. Most of them target
multiple kinases, but some are specific
for different CDKs. Thus, P1446A-05
targets CDK4; PD-0332991 targets
CDK4 and CDK6; P276-00 targets
CDK1, CDK4-cyclin D1, and CDK9-
cyclin T1 complexes and so on. (La-
penna and Giordano, 2009). All are
either in Phase I or Phase II trials for
various types of cancers including
leukemia, melanoma, solid tumors,
and different types of lymphomas. In
some cases, very specific tumor sub-
groups, such as ‘‘cyclin D1 positive
melanoma’’, are being targeted so as to
maximize the chances of observing
efficacy (NCT00835419; www.clini-
caltrials.gov).
However, to make the use of TKIs
feasible and applicable for PCLs, muta-
tion profiling for patient selection will
have to be performed so as to specifi-
cally include individuals with tumors
harboring mutations within corre-
sponding signaling networks, and
therefore likely tumor dependency on
activated MAPK, JAK-STAT, or CDK
pathways.
It is worth to note a significant
concern, which is presented by reports
regarding acquired chemoresistance to
TKIs, which can occur through a
number of mechanisms; i.e., through
newly developed aberrations (Janmaat
et al., 2006; Carter et al., 2009).
Prominent acquired mutation examples
include those demonstrated in BCR-
ABL and KIT in imatinib-resistant
tumors, as well as mutations of EGFR
in gefitinib/erlotinib-resistant tumors
(Gorre et al., 2001; Heinrich et al.,
2003). This phenomenon raises the
question of the value of alternative
therapeutic strategies to multikinase
inhibitors, for example, the use of
mAbs. Combinational strategies of both
types of therapy and their relative
efficacy remain to be explored in
prospective trials in order to be able
to privilege one class over the other in
future therapeutic approaches.
Epigenetic targets: HDAC inhibitors and
demethylating agents
Classic molecular aberrations in cancer
include genetic changes that result in
proto-oncogene activation, tumor sup-
pressor inactivation, or the formation of
fusion oncoproteins. In contrast, epige-
netic changes present a different level
of molecular control that affects gene
expression without altering the DNA
sequence. Cellular chromatin structure
is maintained and regulated through
DNA methylation and histone modifi-
cations, such as histone acetylation. A
number of studies indicate that abnor-
mal activity of histone deacetylases
(HDACs) may lead to overexpression
of oncogenes and downregulation of
tumor suppressor genes and antiproli-
ferative molecules (Marks et al., 2004;
Witt et al., 2009). In response to this
finding, a group of HDAC inhibitors
(HDACi) have been developed. Suber-
oylanilide hydroxamic acid (Vorino-
stat), Valproic acid (Depakote),
Depsipeptide (FR-901228, Romidep-
sin), Panobinostat, and Belinostat all
belong to this group of compounds
(Marks and Xu, 2009). The rationale for
using HDACi in tumor cells has been
confirmed in experimental and clinical
settings by several studies. Suberoyla-
nilide hydroxamic acid, for example, is
able to restore caspase-8 silencing,
whereas Dacinostat can inhibit TLR4-
dependent Th1 but not Th2 effector cell
activation and migration (Brogdon
et al., 2007; Hacker et al., 2009). The
first HDACi to be approved for use in
advanced CTCL patients was vorinostat,
an orally available hydroxamic acid
derivative that inhibits both class I
and II HDACs (Mann et al., 2007).
Responses observed in Phase I/II clin-
ical trials using vorinostat therapy
varied from 24 to 30% (Duvic et al.,
2007; Olsen et al., 2007b). Until now,
the approval is granted only by the
Food Drug Administration, and vorino-
stat currently has not been approved by
the European Medicines Agency,
which restricts its use in Europe.
HDACi is also proved to be active in
a variety of hematological malignan-
cies, including myeloid malignancies,
Hodgkin’s lymphoma, and peripheral
T-cell lymphoma (Prince et al., 2009a).
Other HDACi in development, such as
Romidepsin (Depsipeptide), Panobino-
stat, and Belinostat, demonstrate simi-
lar responses in pilot studies with MF/
SS patients (Gimsing, 2009; Piekarz
et al., 2009; Prince et al., 2009b).
To underline possible synergistic
activities, CTCL cell line experiments
were carried out, which provided some
rationale for HDACi/Bortezomib and
HDACi/PI3K inhibitor combination
therapies (Heider et al., 2009; Wozniak
et al., 2010). Analysis of molecular
events occurring during HDACi treat-
ment provided additional hints on the
CTCL biology. Several biomarkers of
response to HDACi have been identi-
fied, such as HR23B (RAD23B), a
nucleotide excision repair protein that
is also involved in proteolytic degrada-
tion; guanylate cyclase 1A3, the main
receptor for nitric oxide, and angio-
poietin1, a protein largely involved in
the angiogenesis, were consistently
downregulated upon treatment with
HDACi (Ellis et al., 2008; Khan et al.,
2010).
Additional mechanisms to control
gene expression are through miRNAs
that can cause mRNA degradation and/
or repress mRNA translation. An excit-
ing interplay between miR-342 and
miR-199a* in apoptosis inhibition has
been just described as being relevant
for the pathogenesis of SzS (Ballabio
et al., 2010). Several studies showed
that deregulated miRNA expression
is present in CTCL tumor cells,
which opens yet another possibility
for the development of targeted com-
pounds toward different miRNAs, such
www.jidonline.org 521
R Dummer et al.
Cutaneous Lymphomas
as miR-17-92 cluster, miR-21, miR-152,
or miR-214 (Ballabio et al., 2010;
Narducci et al., 2011; van der Fits
et al., 2011b). In the work of Ralfkiaer
et al (2011), a set of five miRNAs was
identified, which can discriminate sam-
ples from primary CTCLs and benign
inflammation lesions. These miRNAs
include upregulated miR-326, miR-
663b, miR-711, and downregulated
miR-203, miR-205 (Ralfkiaer et al.,
2011). miRNA profiling is also shown
to distinguish specific stages of CTCL
lesions; thus, tumor-stage MF is charac-
terized by upregulation of mir-92a,
miR-93, and miR-155 compared with
benign inflammatory disorders (van
Kester et al., 2011). Further descrip-
tion of signaling networks regulated
by specific miRNAs and development
of specific expression profiles will
provide solid grounds for personalized
treatment approaches. First attempt is
already presented by Manfe et al (2010)
describing miR-27a and miR-92b as
being downregulated upon treatment
with g-secretase inhibitor, which sup-
presses the NOTCH pathway.
Hypermethylation of P15, P16,
BCL7a, and several other gene pro-
moters have been reported in PCLs (see
Supplementary Table 1 online). On the
basis of these observations, one could
hypothesize that demethylating agents
may be effective in treatment of CTCLs
and CBCLs as monotherapy or in
combination with other drugs that can
further target tumor cells (Navas et al.,
2002; Scarisbrick et al., 2002; van
Doorn et al., 2005). To date, there
are two registered agents, 50-azacitid-
ine (Vidaza, Celegene Summit, NJ) and
50-aza-20deoxycitidine (Decitabine,
Dacogen, SuperGen, Dublin, CA).
These compounds are structurally
similar, induce hypomethylation, and
are mainly used in the treatment of
myelodysplastic syndromes. Both drugs
are nucleoside analogs and are able to
incorporate into nucleic acids: decita-
bine into DNA, and Vidaza into DNA
and RNA with the help of ribonucleo-
tide reductase. Achieved hypomethyla-
tion is thought to weaken the effects
of gene silencing mechanisms that
have occurred during tumor develop-
ment, and thus result in the relative
gene activation (Garcia-Manero, 2008).
Response rates to Azacitidine are
quite promising in patients with high-
risk myelodysplastic syndrome: com-
plete remissions were seen in 10–17%
(Silverman et al., 2006). Survival esti-
mation within a large randomized
Phase III study in patients with higher-
risk myelodysplastic syndrome was
released recently, showing an increased
overall survival (24.5 vs. 15.0 months)
using Azacitidine as compared with
conventional care (Fenaux et al.,
2009). Decitabine is also proving to
be useful in the treatment of high-risk
myelodysplastic syndrome, as recently
demonstrated in a trial showing CR
rates of 39% using a low-dose regimen
of 5-day 20mgm2 intravenously (Kan-
tarjian et al., 2007).
Proteosome inhibitors
Bortezomib (Velcade, PS-341, MG-
341, Millennium Pharmaceuticals,
Cambridge, MA) is a selective, rever-
sible inhibitor of the proteasome that
has shown marked inhibitory activity
in a variety of cell lines in both
hematological and solid malignancies
(Leonard et al., 2006). It induces
apoptosis through the inhibition of the
ubiquitin–proteasome pathway and has
been already tested in patients with
different lymphoma types (Hennessy
et al., 2004; Strauss et al., 2006).
Bortezomib has been most extensively
studied clinically in the setting of multi-
ple myeloma (Chauhan et al., 2005).
Pre-clinical data also support the
use of Bortezomib in T-cell diseases
(Hamamura et al., 2007). A Phase II
trial of Bortezomib as a single-agent
therapy in PCLs produced an overall
response rate of 67% with relatively
modest toxicities (Zinzani et al., 2007).
These inspiring results should lead to
the initiation of further investigation of
the use of Bortezomib as a single agent
or in combination with other drugs
including HDACs.
CONCLUSION
Currently, CLs are a heterogeneous
group of well-defined diseases primar-
ily affecting the skin, typically charac-
terized by distinct molecular and
prognostic features when compared
with their systemic counterparts. Cuta-
neous lymphomas deserve the special
attention because their diagnosis and
management require an integration of
clinical, dermatopathological, scientific,
and therapeutic expertise that are at
best found in well-trained dermatolo-
gists. Recent scientific developments in
the field have helped develop reliable
systems for diagnosis and staging, and
provided largely improved insight into
the complex molecular biology of this
heterogeneous disease. As a conse-
quence, there are now an increasing
number of new molecules available for
therapeutic interventions, many of
which specifically target molecular
pathways relevant to the development
of disease. A further improvement
depends on the identification of target-
able, tumor cell–specific alterations
that do not interfere with the function
of normal lymphocytes. Genetic ap-
proaches failed to identify consistent
defects until now, suggesting that there
is a wide spectrum of alterations.
From our personal perspective,
successful therapeutic approaches will
apply specific inhibitors of tumor cell
survival combined with immunostimu-
lation. At present, there is a plethora
of new molecules investigated in the
cancer landscape. None of them
appears convincingly attractive for CL.
We are still awaiting new targets
that will facilitate a major advance-
ment. Until then, we will investigate
many molecules on a trial-and-error
basis.
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